{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:27:54Z","timestamp":1792672074496,"version":"4.5.0"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011962","name":"Research Center for Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["78152"],"award-info":[{"award-number":["78152"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119707","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:23:50Z","timestamp":1782318230000},"page":"119707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Innovations in peptide-based targeted therapies for breast cancer: From conjugates to precision delivery"],"prefix":"10.1016","volume":"201","author":[{"given":"Nastaran Daryaei","family":"Ghazani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Shojaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rahbarnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Safary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Akbarzadeh\u2011Khiavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Nabizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119707_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-021-03180-y","article-title":"Detecting prognostic biomarkers of breast cancer by regularized Cox proportional hazards models","volume":"19","author":"Li","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119707_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.783450","article-title":"Breast cancer; discovery of novel diagnostic biomarkers, drug resistance, and therapeutic implications","volume":"9","author":"Afzal","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2026.119707_bib3","article-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022","journal-title":"Breast Cancer [Internet]"},{"key":"10.1016\/j.biopha.2026.119707_bib4","first-page":"17","article-title":"Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy","author":"Ma","year":"2026","journal-title":"Front. Immunol. Vol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119707_bib5","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3390\/cancers13133357","article-title":"Tumor microenvironment: key players in triple negative breast cancer immunomodulation","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119707_bib6","first-page":"2025","article-title":"Tumor-infiltrating immune cells state-implications for various breast cancer subtypes","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib8","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3390\/cancers12102767","article-title":"Non-invasive biomarkers for early detection of breast cancer","volume":"12","author":"Li","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119707_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104191","article-title":"Spotlight on HIV-derived TAT peptide as a molecular shuttle in drug delivery","author":"Maani","year":"2024","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119707_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134160","article-title":"Rational design of an anti-cancer peptide inhibiting CD147\/Cyp A interaction","volume":"1272","author":"Maani","year":"2023","journal-title":"J. Mol. Struct."},{"issue":"11","key":"10.1016\/j.biopha.2026.119707_bib11","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/j.apsb.2022.08.013","article-title":"Smart drug delivery systems for precise cancer therapy","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.biopha.2026.119707_bib12","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"Spec Feature","key":"10.1016\/j.biopha.2026.119707_bib13","first-page":"135","article-title":"Velcade (Bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug. Benefits"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib14","first-page":"1","article-title":"Effect of Bortezomib administration on autophagic cell death in colorectal cancer cells","volume":"1","author":"Erba\u015f","year":"2022","journal-title":"Eurasia J. Mol. Biochem. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib15","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ymthe.2022.01.017","article-title":"Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo","volume":"30","author":"Lange","year":"2022","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12032-021-01509-7","article-title":"Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel","volume":"38","author":"Mehdizadeh","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2026.119707_bib17","first-page":"146","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh","year":"2023","journal-title":"EXCLI J."},{"key":"10.1016\/j.biopha.2026.119707_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/CMAR.S232708","article-title":"Research progress evaluating the function and mechanism of anti-tumor peptides","author":"Pan","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ph16030336","article-title":"2022 FDA TIDES (peptides and oligonucleotides) harvest","volume":"16","author":"Al Musaimi","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/cancers16051032","article-title":"Peptide Therapeutics: unveiling the potential against cancer\u2014a journey through 1989","volume":"16","author":"Musaimi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119707_bib21","article-title":"Recent advances in peptide-based therapeutic strategies for breast cancer treatment","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.32604\/or.2025.062197","article-title":"Unlocking the potential of tumor-targeting peptides in precision oncology","volume":"33","author":"Rehman","year":"2025","journal-title":"Oncol. Res."},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/nano13172476","article-title":"Peptides targeting HER2-positive breast cancer cells and applications in tumor imaging and delivery of chemotherapeutics","volume":"13","author":"Cavallaro","year":"2023","journal-title":"Nanomaterials (Basel)"},{"issue":"11","key":"10.1016\/j.biopha.2026.119707_bib24","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.3390\/ijms25116219","article-title":"Tumor-homing peptides as crucial component of magnetic-based delivery systems: recent developments and pharmacoeconomical perspective","volume":"25","author":"Milewska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119707_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155946","article-title":"Peptides in breast cancer therapy: from mechanisms to emerging drug delivery and immunotherapy strategies","volume":"269","author":"Alaei","year":"2025","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.biopha.2026.119707_bib26","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S562135","article-title":"Tumor targeting with peptide-drug conjugates: showcasing key progress and hurdles","volume":"20","author":"Parang","year":"2026","journal-title":"Drug. Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.37349\/eds.2024.00041","article-title":"Stapled peptides: targeting protein-protein interactions in drug development","volume":"2","author":"Zhang","year":"2024","journal-title":"Explor. Drug. Sci."},{"key":"10.1016\/j.biopha.2026.119707_bib28","author":"Alshawwa","year":"2024","journal-title":"Advancements Early Detection Breast Cancer Innovations Future Directions"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib30","first-page":"171","article-title":"Breast cancer treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.biopha.2026.119707_bib31","series-title":"Seminars in nuclear medicine","first-page":"551","article-title":"Sentinel lymph node methods in breast cancer","author":"Giammarile","year":"2022"},{"key":"10.1016\/j.biopha.2026.119707_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610378","article-title":"Radiotherapy of breast cancer-professional guideline 1st Central-Eastern European professional consensus statement on breast cancer","volume":"28","author":"Polg\u00e1r","year":"2022","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061864","article-title":"Non-surgical definitive treatment for operable breast cancer: current status and future prospects","volume":"15","author":"Shibamoto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119707_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5101078","article-title":"The role of radiotherapy for patients with unresectable locally advanced breast cancer following neoadjuvant systemic therapy","volume":"2023","author":"Wang","year":"2023","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.52711\/2349-2996.2024.00016","article-title":"Current therapy in cancer: advances, challenges, and future directions","volume":"14","author":"Sen","year":"2024","journal-title":"Asian J. Nurs. Educ. Res."},{"issue":"5s","key":"10.1016\/j.biopha.2026.119707_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.6004\/jnccn.2017.0072","article-title":"NCCN guidelines update: evolving radiation therapy recommendations for breast cancer","volume":"15","author":"Salerno","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13058-024-01936-0","article-title":"Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI","volume":"26","author":"Gao","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119707_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness and current knowledge of breast cancer","volume":"50","author":"Akram","year":"2017","journal-title":"Biol. Res."},{"key":"10.1016\/j.biopha.2026.119707_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102988","article-title":"The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice","volume":"153","author":"Claessens","year":"2020","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.biopha.2026.119707_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119707_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol. Rev."},{"issue":"22","key":"10.1016\/j.biopha.2026.119707_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225351","article-title":"Reconsidering aromatase for breast cancer treatment: new roles for an old target","volume":"25","author":"Caciolla","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119707_bib43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fonc.2019.00510","article-title":"Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials","volume":"9","author":"Sayed","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib44","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-020-0153-3","article-title":"Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond","volume":"6","author":"Costa","year":"2020","journal-title":"npj Breast Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib48","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"24","key":"10.1016\/j.biopha.2026.119707_bib49","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119707_bib51","doi-asserted-by":"crossref","unstructured":"Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer, Journal for ImmunoTherapy of Cancer 9(12) (2021) e002597corr1.","DOI":"10.1136\/jitc-2021-002597corr1"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib52","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29933","article-title":"Update on DWI for breast cancer diagnosis and treatment monitoring","volume":"222","author":"Gullo","year":"2024","journal-title":"Am. J. Roentgenol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib53","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cells14171353","article-title":"The role of tumor microenvironment in triple-negative breast cancer and its therapeutic targeting","volume":"14","author":"Vuletic","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/ph19040541","article-title":"Mechanisms of resistance and synergy: the role of tumor microenvironment in HER2-low breast cancer therapy","volume":"19","author":"Basem","year":"2026","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.biopha.2026.119707_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121894","article-title":"The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy","volume":"11","author":"De Santo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119707_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255820","article-title":"Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119707_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.149209","article-title":"c-Myc-targeted therapy in breast cancer: a review of fundamentals and pharmacological Insights","author":"Stipp","year":"2025","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2026.119707_bib58","doi-asserted-by":"crossref","DOI":"10.1039\/D4NA00086B","article-title":"Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies","author":"Chaudhari","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.biopha.2026.119707_bib59","article-title":"The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2455240","article-title":"Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines","volume":"21","author":"Paul","year":"2025","journal-title":"Human. Vaccin. Immunother."},{"key":"10.1016\/j.biopha.2026.119707_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155983","article-title":"Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review","author":"Ghahfarrokhi","year":"2025","journal-title":"Pathol. -Res. Pract."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"npj Breast Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119707_bib65","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/fon-2015-0054","article-title":"The development and use of the E75 (HER2 369\u2013377) peptide vaccine","volume":"12","author":"Clifton","year":"2016","journal-title":"Future Oncol."},{"issue":"15_","key":"10.1016\/j.biopha.2026.119707_bib66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2021.39.15_suppl.542","volume":"39","author":"Patel","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2021.1849140","article-title":"AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence","volume":"30","author":"McCarthy","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2026.119707_bib68","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00262-008-0540-3","article-title":"The E75 HER2\/neu peptide vaccine","volume":"57","author":"Mittendorf","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119707_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"npj Vaccin."},{"key":"10.1016\/j.biopha.2026.119707_bib71","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/imt.14.22","article-title":"The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response","volume":"6","author":"Schneble","year":"2014","journal-title":"Immunotherapy"},{"issue":"13","key":"10.1016\/j.biopha.2026.119707_bib73","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1078-0432.CCR-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127133","article-title":"Correction: Folate receptor-\u03b1 (FOLR1) expression and function in triple negative tumors","volume":"10","author":"Necela","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119707_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.550","article-title":"Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy","author":"Chumsri","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib76","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12935-024-03421-2","article-title":"Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine","volume":"24","author":"Cen","year":"2024","journal-title":"Cancer Cell. Int."},{"issue":"13","key":"10.1016\/j.biopha.2026.119707_bib77","article-title":"Vaccines in breast cancer: challenges and breakthroughs","volume":"13","author":"Fatima","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.biopha.2026.119707_bib78","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.tips.2024.10.013","article-title":"Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors","volume":"45","author":"Shah","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-26511-1","article-title":"silico design of a multi-epitope vaccine against the triple negative breast cancer","volume":"15","author":"Zahraei","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119707_bib80","doi-asserted-by":"crossref","DOI":"10.1089\/cbr.2025.0050","article-title":"Recent breakthroughs in exosome-based drug delivery: a comprehensive review for cancer therapy","author":"Shah","year":"2025","journal-title":"Cancer Biotherapy Radiopharm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib81","article-title":"Advancements in utilizing exosomes for cancer therapy through drug delivery systems: recent developments","volume":"12","author":"Karami","year":"2025","journal-title":"Nanomed. J."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib82","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","article-title":"Engineering exosomes for targeted drug delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib83","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s13346-021-01087-1","article-title":"Exosomal targeting and its potential clinical application","volume":"12","author":"He","year":"2022","journal-title":"Drug. Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib84","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","article-title":"Engineered exosomes from different sources for cancer-targeted therapy","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s44395-025-00023-3","article-title":"Latest developments in advanced exosome engineering for optimized site-specific drug delivery by modulating exosome functionalities in breast cancer","volume":"1","author":"Dawn","year":"2025","journal-title":"Discov. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib86","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2217\/nnm-2022-0328","article-title":"Dual-targeting exosomes for improved drug delivery in breast cancer","volume":"18","author":"Tran","year":"2023","journal-title":"Nanomedicine"},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib87","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7150\/jca.9696","article-title":"cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer","volume":"5","author":"Sohn","year":"2014","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/curroncol32040203","article-title":"Neuropilin-1: a multifaceted target for cancer therapy","volume":"32","author":"Varanasi","year":"2025","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib89","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41598-024-51796-z","article-title":"Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes","volume":"14","author":"Andryszak","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib90","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/1541-7786.MCR-21-0317","article-title":"Therapeutic targeting of stromal-tumor HGF-MET signaling in an organotypic triple-negative breast tumor model","volume":"20","author":"Singh","year":"2022","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-022-01501-7","article-title":"Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS\/MAPK pathway activation","volume":"24","author":"Tang","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib92","first-page":"46","article-title":"Harnessing exosomes for targeted therapy: strategy and application","volume":"5","author":"Ren","year":"2024","journal-title":"Biomater. Transl."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib93","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.201800275","article-title":"Systematic evolution of ligands by exosome enrichment: a proof-of-concept study for exosome-based targeting peptide screening","volume":"3","author":"Liu","year":"2019","journal-title":"Adv. Biosyst."},{"key":"10.1016\/j.biopha.2026.119707_bib95","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jconrel.2024.02.037","article-title":"Smart exosomes enhance PDAC targeted therapy","volume":"368","author":"Creeden","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib96","first-page":"27","article-title":"Exosome surface modification and functionalization: a narrative review of emerging technologies and their application potential in precision medicine","volume":"2","author":"Chao","year":"2025","journal-title":"Adv. Technol. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib97","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1021\/acsabm.2c00015","article-title":"Modified bovine milk exosomes for doxorubicin delivery to triple-negative breast cancer cells","volume":"5","author":"Pullan","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.biopha.2026.119707_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/IJN.S440619","article-title":"Engineered exosomes carrying miR-588 for treatment of triple negative breast cancer through remodeling the immunosuppressive microenvironment","volume":"19","author":"Zhang","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib99","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/pharmaceutics17101336","article-title":"Exosome-based drug delivery: a next-generation platform for cancer, infection, neurological and immunological diseases, gene therapy and regenerative medicine","volume":"17","author":"Serrano","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib100","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/s41467-025-59377-y","article-title":"Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors","volume":"16","author":"Liang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119707_bib101","article-title":"Reinforced immunotherapy of M1 macrophage-derived exosomes with CEL on TNBC via regulating macrophage functions","author":"Yu","year":"2025","journal-title":"J. Adv. Res."},{"issue":"19","key":"10.1016\/j.biopha.2026.119707_bib102","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1039\/D0NR00523A","article-title":"Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer","volume":"12","author":"Li","year":"2020","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib103","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1039\/D5RA04927J","article-title":"Hybrid exosomes: a rising horizon for precision cancer therapy","volume":"16","author":"Sonar","year":"2026","journal-title":"RSC Adv."},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cells14171353","article-title":"The role of tumor microenvironment in triple-negative breast cancer and its therapeutic targeting","volume":"14","author":"Vuletic","year":"2025","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib105","article-title":"Harnessing exosomes as a platform for drug delivery in breast cancer: a systematic review for in vivo and in vitro studies","volume":"32","author":"Gharavi","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119707_bib106","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1039\/D4NA00501E","article-title":"A comprehensive review of challenges and advances in exosome-based drug delivery systems","volume":"6","author":"Palakurthi","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.biopha.2026.119707_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121137","article-title":"M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages","volume":"278","author":"Gunassekaran","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119707_bib108","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","article-title":"Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy","volume":"363","author":"Tao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119707_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114661","article-title":"Targeted drug delivery of cancer cell-derived extracellular vesicles decorated with a VEGFR-binding peptide","volume":"252","author":"Kim","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2026.119707_bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biomaterials.2019.05.004","article-title":"Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy","volume":"211","author":"Cheng","year":"2019","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib111","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/stcltm\/szae027","article-title":"Exploring the clinical transition of engineered exosomes designed for intracellular delivery of therapeutic proteins","volume":"13","author":"Kim","year":"2024","journal-title":"Stem Cells Transl. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib112","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"issue":"47","key":"10.1016\/j.biopha.2026.119707_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202407370","article-title":"Targeting BRIX1 via engineered exosomes induces nucleolar stress to suppress cancer progression","volume":"11","author":"Gan","year":"2024","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib114","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4048\/jbc.2024.0262","article-title":"Utilizing miR-34a-loaded HER2-targeting exosomes to improve breast cancer treatment: insights from an animal model","volume":"28","author":"Sun","year":"2025","journal-title":"J. Breast Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/mt.2012.180","article-title":"Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells","volume":"21","author":"Ohno","year":"2013","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib116","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1096\/fj.201902434R","article-title":"Exosomes co-expressing AQP5-targeting miRNAs and IL-4 receptor-binding peptide inhibit the migration of human breast cancer cells","volume":"34","author":"Park","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2026.119707_bib117","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fbioe.2023.1254356","article-title":"Engineered exosomes as drug and RNA co-delivery system: new hope for enhanced therapeutics?","volume":"11","author":"Chen","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119707_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114462","article-title":"Breaking barriers: engineering extracellular vesicles for enhanced endosomal escape and therapeutic delivery","volume":"389","author":"Kim","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119707_bib119","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S572435","article-title":"Strategies, challenges and application prospects for exosome engineering modifications in tumor targeted therapeutics","volume":"21","author":"Ge","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines13040344","article-title":"Advancing breast cancer treatment: the role of immunotherapy and cancer vaccines in overcoming therapeutic challenges","volume":"13","author":"Palma","year":"2025","journal-title":"Vaccines"},{"issue":"33","key":"10.1016\/j.biopha.2026.119707_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202403199","article-title":"Immunogenicity of extracellular vesicles","volume":"36","author":"Xia","year":"2024","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib122","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","article-title":"Emerging role of exosomes in cancer therapy: progress and challenges","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib123","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.3390\/ijms23179930","article-title":"Exosomes in cancer diagnosis and therapy","volume":"23","author":"Ahmad","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib124","article-title":"Clinical trial status of exosomes-based cancer theranostics","volume":"4","author":"Sonar","year":"2024","journal-title":"Clin. Transl. Discov."},{"issue":"null","key":"10.1016\/j.biopha.2026.119707_bib125","article-title":"Peptide-based nanocarriers for targeted drug delivery: recent advances, strategies, and therapeutic frontiers","volume":"21","author":"Adnan","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13061415","article-title":"Peptide-based nanoparticle for tumor therapy","volume":"13","author":"Thongpon","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119707_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114195","article-title":"Peptide-targeted nanoparticles for tumor therapy","volume":"387","author":"Sidorenko","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib128","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41598-025-90107-y","article-title":"Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery","volume":"15","author":"Rahdari","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119707_bib129","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fcell.2024.1520078","article-title":"Nanoparticle accumulation and penetration in 3D tumor models: the effect of size, shape, and surface charge","volume":"12","author":"Cybulski","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib130","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/pharmaceutics15071827","article-title":"Cyclic RGD-functionalized pH\/ROS dual-responsive nanoparticle for targeted breast cancer therapy","volume":"15","author":"Yao","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119707_bib131","article-title":"Enhanced anti-tumor efficacy and tumor accumulation of Tamoxifen through cRGD functionalized cholesterol based lipopolymeric nanoparticles for targeted breast cancer therapy","volume":"90","author":"Mazumdar","year":"2023","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119707_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpt.2026.01.004","article-title":"Integrin \u03b13 (ITGA3) expression across breast cancer subtypes: prognosis and therapeutic relevance","author":"Ma","year":"2026","journal-title":"Cancer Pathog. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib133","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1038\/s41598-025-89497-w","article-title":"A machine learning-based investigation of integrin expression patterns in cancer and metastasis","volume":"15","author":"Shadman","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib134","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/cancers11020139","article-title":"Therapeutic potential of a novel \u03b1v\u03b23 antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type","volume":"11","author":"Hill","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031745","article-title":"The effects of \u03b1v\u03b23 integrin blockage in breast tumor and endothelial cells under hypoxia in vitro","volume":"23","author":"Casali","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib136","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/cam.23332","article-title":"Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion","volume":"6","author":"Perrot-Applanat","year":"2012","journal-title":"Cell. Adh Migr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib137","doi-asserted-by":"crossref","first-page":"a006478","DOI":"10.1101\/cshperspect.a006478","article-title":"V integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"43","key":"10.1016\/j.biopha.2026.119707_bib138","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1039\/C5NR04867B","article-title":"Anti-HER2\/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells","volume":"7","author":"Mu","year":"2015","journal-title":"Nanoscale"},{"issue":"29","key":"10.1016\/j.biopha.2026.119707_bib139","doi-asserted-by":"crossref","first-page":"23136","DOI":"10.1039\/D5RA01016K","article-title":"Ultrasound-mediated paclitaxel-loaded EGFR nanoparticles for targeted therapy in breast cancer","volume":"15","author":"Xu","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/biom16010027","article-title":"From mechanism to medicine: peptide-based approaches for cancer diagnosis and therapy","volume":"16","author":"Gouveia","year":"2025","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.biopha.2026.119707_bib141","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1021\/acsbiomaterials.3c01332","article-title":"Collagen-binding nanoparticles for paclitaxel encapsulation and breast cancer treatment","volume":"9","author":"Passos","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.biopha.2026.119707_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122618","article-title":"Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer","volume":"633","author":"Conte","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119707_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113786","article-title":"Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance","volume":"383","author":"Ding","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119707_bib144","doi-asserted-by":"crossref","DOI":"10.1039\/D5NA00907C","article-title":"Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity","author":"Saifullah","year":"2026","journal-title":"Nanoscale Adv."},{"issue":"32","key":"10.1016\/j.biopha.2026.119707_bib145","doi-asserted-by":"crossref","first-page":"13322","DOI":"10.1039\/D3NR00800B","article-title":"A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78","volume":"15","author":"Shin","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119707_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113381","article-title":"Peptide-modified bioresponsive chondroitin sulfate micelles for targeted doxorubicin delivery in triple-negative breast cancer","volume":"227","author":"Yu","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib147","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41598-025-33108-1","article-title":"Computational characterization of GRP78 binding sites on mitochondrial GPX4: implications for targeting ferroptosis in triple-negative breast cancer","volume":"16","author":"Youssef","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119707_bib148","article-title":"Ligand-functionalized core\u2013shell nanoparticles for precision therapy of luminal A breast cancer: emerging strategies, clinical challenges, and future perspectives","volume":"118","author":"Mohamed Ali","year":"2026","journal-title":"J. Drug. Deliv. Sci. Technol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib149","doi-asserted-by":"crossref","first-page":"10102","DOI":"10.1021\/acsami.1c23166","article-title":"Sequential delivery of quercetin and paclitaxel for the fibrotic tumor microenvironment remodeling and chemotherapy potentiation via a dual-targeting hybrid micelle-in-liposome system","volume":"14","author":"Duan","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"40","key":"10.1016\/j.biopha.2026.119707_bib150","doi-asserted-by":"crossref","first-page":"46721","DOI":"10.1021\/acsami.3c11561","article-title":"Albumin nanoparticles surface decorated with a tumor-homing peptide help in selective killing of triple-negative breast cancer cells","volume":"15","author":"Pal","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2026.119707_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125574","article-title":"LDLR-targeted orlistat therapeutic nanoparticles: peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines","volume":"676","author":"Bebawy","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119707_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123226","article-title":"F3 peptide functionalized liquid crystalline nanoparticles for delivering Salinomycin against breast cancer","volume":"643","author":"Kumar","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119707_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113357","article-title":"Peptide-functionalized zinc oxide nanoparticles for the selective targeting of breast cancer expressing placenta-specific protein 1","volume":"227","author":"Cagliani","year":"2023","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib154","first-page":"1572","article-title":"Peptide-functionalized nanomedicine: advancements in drug delivery","volume":"30","author":"Omidian","year":"2025","journal-title":"Diagn. Biomed. Appl. Mol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1039\/D4PM00249K","article-title":"Peptide-derived gold nanoparticles as a promising delivery system for Src targeting siRNA in breast cancer cells","volume":"2","author":"Suryakanta","year":"2025","journal-title":"RSC Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib156","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s13346-023-01330-x","article-title":"Molecular imprinting of miR-559 on a peptide-immobilized poly L-DOPA\/silica core-shell and in vitro investigating its effects on HER2-positive breast cancer cells","volume":"13","author":"Mohammadzade","year":"2023","journal-title":"Drug. Deliv. Transl. Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib157","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1007\/s00210-024-03068-w","article-title":"Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21\/AKT\/ERK signaling axis: in-silico and in vitro studies","volume":"397","author":"Abdulmalek","year":"2024","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119707_bib158","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1021\/acsnano.4c14625","article-title":"Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics","volume":"19","author":"Zhao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119707_bib159","article-title":"IF-7 and GALA modified PEG-PDMAEMA loaded SOX10 siRNA nanoparticles: preparation, cellular delivery, and inhibition on progression of triple negative breast cancer and its bone metastasis in vitro","volume":"100","author":"Li","year":"2024","journal-title":"J. Drug. Deliv. Sci. Technol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119707_bib160","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309917","article-title":"Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy","volume":"11","author":"Kim","year":"2024","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib161","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s13346-024-01638-2","article-title":"Lipid nanoparticles-based RNA therapies for breast cancer treatment","volume":"14","author":"Serpico","year":"2024","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119707_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114030","article-title":"Formulation methods for peptide-modified lipid nanoparticles","volume":"385","author":"Miyasaki","year":"2025","journal-title":"J. Control. Release"},{"issue":"30","key":"10.1016\/j.biopha.2026.119707_bib163","doi-asserted-by":"crossref","first-page":"35248","DOI":"10.1021\/acsami.1c02074","article-title":"Peptide-targeted high-density lipoprotein nanoparticles for combinatorial treatment against metastatic breast cancer","volume":"13","author":"Jiang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2026.119707_bib164","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2020.02.010","article-title":"A dual receptors-targeting and size-switchable \u201ccluster bomb\u201d co-loading chemotherapeutic and transient receptor potential ankyrin 1 (TRPA-1) inhibitor for treatment of triple negative breast cancer","volume":"321","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib165","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10717544.2019.1576801","article-title":"pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer","volume":"26","author":"Wan","year":"2019","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119707_bib166","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.2147\/IJN.S479125","article-title":"pH-responsive charge-reversal smart nanoparticles for co-delivery of mitoxantrone and copper ions to enhance breast cancer chemo-chemodynamic combination therapy","volume":"19","author":"Tan","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib167","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-22-3559","article-title":"Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119707_bib168","article-title":"A redox-responsive nanoparticle with RGD-targeted effect for photo-chemo therapy of triple-negative breast cancer","volume":"31","author":"Yu","year":"2025","journal-title":"Mater. Today Nano"},{"issue":"48","key":"10.1016\/j.biopha.2026.119707_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202408581","article-title":"Dual-responsive shape-transformable charge-reversible nanoparticles combined with chemo-photodynamic-immunotherapy for the treatment of breast cancer and lung metastasis","volume":"34","author":"Jia","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biopha.2026.119707_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123249","article-title":"Polydopamine-coated ferric oxide nanoparticles for R848 delivery for photothermal immunotherapy in breast cancer","volume":"644","author":"Yuan","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib171","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1039\/D2NH00590E","article-title":"cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer","volume":"8","author":"Zou","year":"2023","journal-title":"Nanoscale Horiz."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib172","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s42004-023-01079-x","article-title":"A peptide derived from interleukin-10 exhibits potential anticancer activity and can facilitate cell targeting of gold nanoparticles loaded with anticancer therapeutics","volume":"6","author":"Chang","year":"2023","journal-title":"Commun. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib173","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s12272-024-01514-0","article-title":"Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition","volume":"47","author":"Lo","year":"2024","journal-title":"Arch. Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib174","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12645-024-00299-7","article-title":"Synergistic breast cancer therapy with RGD-decorated liposomes co-delivering mir-34a and cisplatin","volume":"15","author":"Bardania","year":"2024","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119707_bib175","first-page":"2025","article-title":"Trends in the research and development of peptide drug conjugates: artificial intelligence aided design","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib176","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody\u2013drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib177","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide\u2013drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib178","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D0CS00556H","article-title":"Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)","volume":"50","author":"Cooper","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib179","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide\u2013drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib181","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide\u2013drug conjugates as next-generation therapeutics: exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering"},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib182","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70040","article-title":"Peptide-drug conjugates: a new hope for cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.biopha.2026.119707_bib184","article-title":"Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models","author":"Chen","year":"2025","journal-title":"Chin. Chem. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib185","doi-asserted-by":"crossref","first-page":"170","DOI":"10.15212\/bioi-2023-0006","article-title":"HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy","volume":"4","author":"Liang","year":"2023","journal-title":"Bio Integr."},{"issue":"22","key":"10.1016\/j.biopha.2026.119707_bib186","doi-asserted-by":"crossref","first-page":"15123","DOI":"10.1021\/acs.jmedchem.2c00968","article-title":"In silico exploration and biological evaluation of bispecific peptides derived from anti-HER2 antibodies and peptide\u2013camptothecin conjugates for HER2-positive breast cancer","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119707_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116032","article-title":"Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors","volume":"264","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119707_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107371","article-title":"Discovery of novel HER2 targeting peptide-camptothecin conjugates with effective suppression for selective cancer treatment","volume":"147","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib189","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3602","article-title":"Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells","volume":"30","author":"Sharma","year":"2024","journal-title":"J. Pept. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119707_bib190","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers11121826","article-title":"Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials","volume":"11","author":"Maennling","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib191","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131458","article-title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"issue":"21","key":"10.1016\/j.biopha.2026.119707_bib192","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib193","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acsmedchemlett.4c00480","article-title":"A conjugate of an EGFR-binding peptide and doxorubicin shows selective toxicity to triple-negative breast cancer cells","volume":"16","author":"Than","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib194","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70021","article-title":"DiWB-1: a luteinizing hormone releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with enhanced tumor selectivity and PI3K inhibition efficacy","volume":"358","author":"Zhang","year":"2025","journal-title":"Arch. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib195","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.apsb.2023.03.024","article-title":"Self-assembly of CXCR4 antagonist peptide\u2013docetaxel conjugates for breast tumor multi-organ metastasis inhibition","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"13","key":"10.1016\/j.biopha.2026.119707_bib196","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1021\/acs.jmedchem.4c00511","article-title":"Development of peptide paratope mimics derived from the anti-ROR1 antibody and long-acting peptide\u2013drug conjugates for targeted cancer therapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib197","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/acs.molpharmaceut.3c00189","article-title":"Peptide\u2013drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice","volume":"20","author":"Ziaei","year":"2023","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2026.119707_bib198","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1039\/D4DT00497C","article-title":"Dual FGFR-targeting and pH-activatable ruthenium\u2013peptide conjugates for targeted therapy of breast cancer","volume":"53","author":"Franco Machado","year":"2024","journal-title":"Dalton Trans."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib199","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3390\/ijms24043400","article-title":"Targeting the gastrin-releasing peptide receptor (GRP-R) in cancer therapy: development of bombesin-based peptide\u2013drug conjugates","volume":"24","author":"Gomena","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2026.119707_bib200","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1021\/acs.jmedchem.3c00631","article-title":"Synthesis and evaluation of a monomethyl auristatin E\u2500integrin \u03b1v\u03b26 binding peptide\u2013drug conjugate for tumor targeted drug delivery","volume":"66","author":"Davis","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119707_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117264","article-title":"PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis","volume":"178","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib202","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.3390\/ijms24054646","article-title":"Transcytosable peptide-paclitaxel prodrug nanoparticle for targeted treatment of triple-negative breast cancer","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib203","article-title":"Precise HER2 protein degradation via peptide-conjugated photodynamic therapy for enhanced breast cancer immunotherapy","volume":"12","author":"Guo","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"issue":"17","key":"10.1016\/j.biopha.2026.119707_bib204","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.3390\/molecules30173533","article-title":"EGFR-targeted photodynamic treatment of triple negative breast cancer cell lines using porphyrin\u2013peptide conjugates: synthesis and mechanistic insight","volume":"30","author":"Malacarne","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119707_bib205","first-page":"47","article-title":"An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer","volume":"22","author":"Sun","year":"2023","journal-title":"Bioact. Mater."},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib206","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1016\/j.apsb.2025.06.012","article-title":"A dual-targeting peptide\u2013drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2026.119707_bib207","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jconrel.2024.07.074","article-title":"Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate","volume":"375","author":"Kim","year":"2024","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.biopha.2026.119707_bib208","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202410288","article-title":"Peptide-drug conjugate for therapeutic reprogramming of tumor-associated macrophages in breast cancer","volume":"12","author":"Lepland","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2026.119707_bib209","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.10.027","article-title":"Therapeutic vaccines for breast cancer: has the time finally come?","volume":"160","author":"Corti","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib210","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"26","key":"10.1016\/j.biopha.2026.119707_bib211","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib212","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70040","article-title":"Peptide-drug conjugates: a new hope for cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J. Pept. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib213","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/D0CS00556H","article-title":"Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs)","volume":"50","author":"Cooper","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119707_bib214","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008817","article-title":"Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma","volume":"12","author":"M\u00f8rk","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119707_bib215","article-title":"Current landscape and future directions of neoantigen vaccines: a new era of personalized cancer immunotherapy","author":"Wang","year":"2026","journal-title":"Innovation"},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib216","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1021\/acs.oprd.4c00399","article-title":"Process analytical technology for real-time monitoring of pharmaceutical bioconjugation reactions","volume":"29","author":"Ralbovsky","year":"2025","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.biopha.2026.119707_bib217","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.2147\/IJN.S472038","article-title":"Strategies for targeting peptide-modified exosomes and their applications in the lungs","volume":"19","author":"Qiu","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.biopha.2026.119707_bib218","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.drudis.2021.01.022","article-title":"Converting peptides into drugs targeting intracellular protein\u2013protein interactions","volume":"26","author":"Philippe","year":"2021","journal-title":"Drug. Discov. Today"},{"issue":"9","key":"10.1016\/j.biopha.2026.119707_bib219","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1021\/acs.accounts.4c00024","article-title":"Beyond N-alkylation: synthesis, structure, and function of N-amino peptides","volume":"57","author":"Angera","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biopha.2026.119707_bib220","article-title":"Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications","author":"Tan","year":"2025","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib221","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119707_bib222","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012217","article-title":"Shared epitopes create safety and efficacy concerns in several cancer vaccines","volume":"13","author":"Kellermann","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib223","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib224","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide-drug conjugates: an emerging direction for the next generation of peptide therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119707_bib226","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10911-020-09470-3","article-title":"Methodological advancements for investigating intra-tumoral heterogeneity in breast cancer at the bench and bedside","volume":"25","author":"Baek","year":"2020","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib227","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65477-6","article-title":"Integrated spatial proteomic analysis of breast cancer heterogeneity unravels cancer cell phenotypic plasticity","volume":"16","author":"Mardamshina","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119707_bib228","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-3444-7_19","article-title":"Patient-derived tumor xenograft models of breast cancer","volume":"1406","author":"Suarez","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119707_bib229","article-title":"Precision-cut tumor slices (PCTS) as an ex vivo model in immunotherapy research","volume":"11","author":"Dimou","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119707_bib230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2026.119707_bib231","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2026.119707_bib232","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","volume":"20","author":"Herdiana","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2026.119707_bib233","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13904","article-title":"Regulation of exosomes as biologic medicines: regulatory challenges faced in exosome development and manufacturing processes","volume":"17","author":"Wang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119707_bib234","doi-asserted-by":"crossref","unstructured":"J.R. Youssef, E.M. Elgammal, D.M. Mahdy, N.F. Ghazi, G. Bebawy, Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale-Up Considerations, Pharmaceutical Research (2026).","DOI":"10.1007\/s11095-026-04095-3"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:32:11Z","timestamp":1785911531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":234,"alternative-id":["S0753332226007432"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119707","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in peptide-based targeted therapies for breast cancer: From conjugates to precision delivery","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119707"}}